Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Monotherapy and CYP2C19 Genotype Testing After PCI in AF
2023-508904-39-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of rivaroxaban in Atrial fibrillation (AFib), coronary arteriosclerosis, myocardial infarction (MI) and 1 more, sponsored by Amsterdam University Medical Center. Planned start Mar 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosismyocardial infarction (MI)ischemic stroke
Beyond the preview
Go deeper on 2023-508904-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508904-39-00.